Aktualisierte Fassung

H. Partsch; W. Blättler

doi:10.1055/s-0037-1617241

Phlebologie, Inhaltsverzeichnis

Phlebologie 2000; 29(04): 106-113
DOI: 10.1055/s-0037-1617241

Leitlinien der DGP

Schattauer GmbH

Aktualisierte Fassung

Leitlinien zur Thromboembolie-Prophylaxe

Autoren

H. Partsch
W. Blättler

Abstract

Volltext

Referenzen

Literatur
1 Nicolaides AN, Bergqvist D, Hull R. Prevention of venous thromboembolism. International Consensus Statement (Guidelines according to scientific evidence). Int Angiol 1997; 16: 3-38.
2 Fifth ACCP Consensus Conference on Antithrombotic Therapy. Chest 1998 114. Supplementum.
2a Verstraete M, Prentice CRM, Samama M, Verhaege R. on behalf of a European Working Group.. A European view on the North American fifth consensus on antithrombotic therapy. Chest 2000; 117: 1755-70.
3 Leitlinie zur stationären und ambulanten Thromboembolie-Prophylaxe in der Chirurgie. Deutsche Gesellschaft für Chirurgie 1997 AWMF online awmf@uni-duesseldorf.de.
4 Hach-Wunderle V, Haas S. (Hrsg.). Thromboembolie- Prophylaxe in der inneren und operativen Medizin. Berlin, Heidelberg, New York: Springer Verlag; 1997
5 Prevention of venous thrombosis and pulmonary embolism (Consensus Conference, NIH). JAMA 1986; 256: 744-57.
6 Haas S. Thrombose in der Unfall- und Orthopädischen Chirurgie. Unfallchirurg 1997; 100: 307-19.
7 European Consensus Statement: Prevention of venous thromboembolism.. Internat. Angiology 1992; 11: 151-9.
8 Bergqvist D, Comerota A, Nicolaides AN, Scurr JH. Prevention of venous thromboembolism. London, Los Angeles, Nicosia: Med-Orion Publishing Company; 1994
9 Bounameaux H. Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases. New York: Marcel Dekker; 1994
10 Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg 1992; 127: 310-3.
11 Ginsberg JS. Thromboembolism and Pregnancy. Thromb Haemost 1999; 82: 620-5.
12 Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
13 Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-3.
14 Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FR, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-7.
15 Kon Koh K, Horne III MK, Canon III RO. Effects of Hormone Replacement Therapy on Coagulation, Fibrinolysis, and Thrombosis Risk in Postmenopausal Women. Thromb Haemost 1999; 82: 626-33.
16 Samama MM, Cohen AT, Darmon J-Y, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson C-G, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. NEJM 1999; 341: 793-800.
17 Pineo GF, Hull RD. A comparison of preoperatrive dalteparin with postoperative dalteparin and with warfarin sodium for prophylaxis against deep vein thrombosis after total hip replacement during the acute hospital stay. XVIIth Congress of the ISTH, Washington. Thromb Haemost. 1999 (Suppl. August): 376.
18 Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anaesthetic management. Anaesth Analg 1997; 85: 874-85.
19 Thompson GE. Anticoagulation in the Setting of Epidural or Spinal Anesthesia/Analgesia. Thromb Haemost 1999; 82: 913-7.
20 Warkentin TE, Levine MN, Hirsch J, Horsewood P, Roberts RS, Tech M, Kent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractioned heparin. NEJM 1995; 332: 1330-34.
21 Arzneimittel-Schnellinformation/ASI 3/96) des BfArM. Deutsches Ärzteblatt 1996; 93: A987.
22 Montreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractioned heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.
23 Gehling H, Giannadakis K, Lefering R, Hessmann M, Achenbach S, Gotzen L. Prospective randomized pilot study of ambulatory prevention of thromboembolism, 2 times 500 mg aspirin (ASS) vs. Clivarin 1750. Unfallchirurg 1998; 101: 42-9.
23a Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-302.
24 Eriksson BI, Ekman St Kälebo P, Zachrission B, Bach D, Close Ph. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, GCP 39393. Lancet 1996; 347: 635-9.
25 Partsch H, Kahn P. Venöse Strömungsbeschleunigung in Bein und Becken durch »Anti- thrombose-Strümpfe«. Klinikarzt 1982; 11: 609-15.
26 Mercett ND, Hanel KC. Ischaemic complications of graduated compression stockings in the treatment of deep venous thrombosis. Postgrad Med J 1993; 69: 232-4.
27 Chylarecki CF, Hierholzer G, Rudofsky G. Physikalische Thromboseprophylaxe mit motorisierter Sprunggelenkbewegungsschiene. Unfallchirurgie 1995; 21: 137-47.
28 Adolf J, Fritsche HM, Haas S, Hennig FF, Horbach T, Kastl S, Koppenhagen K, Michaelis HC, Rhamanzadeh R, Summa W, Wagner W, Weber U, Wolf H. Comparison of 3,000 IU aXa of the low molecular weight heparin certoparin with 5,000 IU aXa in prevention of deep vein thrombosis after total hip replacement. German Thrombosis Study Group. Int Angiol 1999; 18: 122-6.
29 Wulf H. Thromboembolieprophylaxe und rückenmarksnahe Regionalanästhesie. Anästh Intensivmed 1995; 36: 216-7.
30 Dahl OE, Andreassen G, Aspelin T, Muller C, Mathiesen P, Nyhus S, Abdelnoor M, Solhaug JH, Arnesen H. Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomised, placebo- controlled study with dalteparin. Thromb Haemost 1997; 77: 26-31.
31 Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Roseli R, Abad A. Upper extremity deep venous thrombosis in cancer patients with venous access devices-Prophylaxis with low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75: 251-3.
32 Toglia MR, Weg JG. Venous thromboembolism during pregnancy. NEJM 1996; 335: 108-14.
33 Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardinge E, Brenner B, Dulitzky M, Nielsen JD, Boda Z, Turi S, Mac-Gillavry MR, Hamulyak J, Theunissen IM, Hunt BJ, Buller HR. Safety of low-molecularweight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81: 668-72.
34 Hunt BJ, Doughty HA, Majumdar G, Copplestone A, Kerslake A, Buchanan N, Hughes G, Khamashta M. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 77: 39-43.